Leinco Technologies

Anti-Mouse PD-L2 (B7-DC) - APC

Product Code:
 
LEI-C2295
Product Group:
 
Primary Antibodies
Host Type:
 
Rat
Antibody Isotype:
 
IgG2a κ
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
TY25
Regulatory Status:
 
RUO
Target Species:
 
Mouse
Application:
 
Flow Cytometry
Shipping:
 
2-8°C
Storage:
 
This Allophyc°Cyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-C2295-100ug100 ug£303.00
Quantity:
LEI-C2295-250ug250 ug£492.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Antigen Distribution:
PD-L2 is expressed on macrophages and a subset of dendritic cells (DCs).
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
Allophycocyanin (APC)
Format:
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Purified transfected mouse B7-DC cell line
Long Description:
PD-L2 antibody, clone TY25, recognizes mouse programmed death ligand 2 (PDL-2), also known as B7-DC and CD273. PD-L2 is a 42 kDa type I transmembrane glycoprotein that belongs to the B7 family of the immunoglobulin (Ig) receptor superfamily. PD-L2 is an inhibitory ligand primarily expressed on antigen-presenting cells, including macrophages and a subset of dendritic cells (DCs). Its receptor, PD-1, is expressed by CD4-CD8- thymocytes as well as CD4 and CD8 T cells, monocytes, DCs, and B cells upon activation1. Binding of PD-L2 to PD-1 on CD4 and CD8 T cells inhibits T cell receptor (TCR) signaling, negatively regulating T cell proliferation, cytokine production, and cytotoxic activity2. PD-L2 is expressed on many tumor types3,4 and is associated with unfavorable prognosis in patients with solid tumors5.
NCBI Gene:
58205
Target:
PD-L2

References

1. Francisco LM, et al. (2010) Immunol Rev. 236:219-242 2. Latchman Y, et al. (2001) Nat Immunol. 2(3):261-8 3. Ahmad SM, et al. (2018) Oncoimmunology. 7:e1390641 4. Panjwani PK, et al. (2018) Hum Pathol. 71:91?9 5. Yang H, et al. (2019) Front Oncol. 9:47